Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lauren Christine Harshman, Yu-Hui Chen, Glenn Liu, Michael Anthony Carducci, David Frazier Jarrard, Robert Dreicer, Noah M. Hahn, Jorge A. Garcia, Maha Hussain, Daniel H. Shevrin, Mario A. Eisenberger, Manish Kohli, Yu-Ning Wong, Matthew M. Cooney, Nicholas J. Vogelzang, Joel Picus, Robert S. DiPaola, Christopher Sweeney
Institutions: Dana-Farber Cancer Institute, Harvard University, Dana-Farber/Harvard Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, UW Health University Hospital, University of Virginia, Cleveland Clinic, University of Michigan, Endeavor Health, Mayo Clinic, Fox Chase Cancer Center, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Comprehensive Cancer Centers of Nevada, Washington University in St. Louis, University of Kentucky
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2600713540